All In Biotech

Free tool

FAERS Monitor: Reyvow

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 211280 or its brand name (Reyvow, Lasmiditan Succinate). Reports on generic versions are filed under their own applications.

Reports

1,163

Serious

206

18% of reports

Hospitalization

63

Death reported

13

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • dizziness210
  • drug ineffective137
  • feeling abnormal118
  • somnolence109
  • migraine89
  • nausea86
  • sedation79
  • fatigue68
  • headache66
  • paraesthesia58
  • hallucination44
  • hypoaesthesia31
  • insomnia31
  • serotonin syndrome28
  • euphoric mood27

Reports by year received

View as table
YearReports
2020334
2021398
2022128
202383
202495
202575
202650

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,996 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
sedationSignal7954.744.24,105
euphoric moodSignal2747.832.91,188
serotonin syndromeSignal2826.418.3659
migraineSignal8916.913.81,318
hallucinationSignal4410.67.9373
somnolenceSignal1099.88.2860
feeling abnormalSignal1188.97.5830
dizzinessSignal2107.66.71,229
paraesthesiaSignal586.75.2276
hypoaesthesiaSignal313.72.660
insomniaSignal312.11.517
nausea862.01.641
headache661.91.528
drug ineffective1371.91.659
fatigue681.61.314

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.